Sugi Predict

Sugi Predict / Compounds / SCHEMBL4822182

SCHEMBL4822182

SCHEMBL4822182

ClCc1nc2cccnc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.53
▸ POLB P06746 1/20 0.50
▸ NPC1 O15118 11/20 0.45
▸ RAB9A P51151 8/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ AKR1B1 P15121 1/20 0.41
▸ ALDH1A1 P00352 7/20 0.40
▸ KDM4E B2RXH2 5/20 0.40
▸ RUNX1 Q01196 3/20 0.40
▸ CBFB Q13951 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ GLA P06280 2/20 0.40
▸ HPGD P15428 4/20 0.36
▸ LMNA P02545 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ ATM Q13315 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2756164 0.81 POLB (0.58) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL14421725 0.81 PDK1 (0.53) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL2179891 0.81 UBE2T (0.55) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL2175795 0.81 PDK1 (0.53) PDK1POLBNPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL30209032 0.80 UBE2T (0.53) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL15920638 0.79 POLB (0.59) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL26485577 0.77 POLB (0.50) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL18281906 0.77 PDK1 (0.49) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL1272700 0.75 PDK1 (0.46) PDK1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL1272703 0.75 POLB (0.48) PDK1POLBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230406830-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS Valo Health, LLC 2023-12-21 — — US disclosed
US-11414392-B2 [6,6] fused bicyclic HDAC8 inhibitors VALO HEALTH, INC. (US) 2022-08-16 — — US disclosed
US-20210139439-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS VALO HEALTH, INC. 2021-05-13 — — US disclosed
US-20210139439-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS VALO HEALTH, INC. 2021-05-13 — — US disclosed
US-10829460-B2 [6,6] fused bicyclic HDAC8 inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-11-10 — — US disclosed
US-10829460-B2 [6,6] fused bicyclic HDAC8 inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-11-10 — — US disclosed
US-20190308946-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS VALO HEALTH, INC. 2019-10-10 — — US disclosed
US-20190308946-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS VALO HEALTH, INC. 2019-10-10 — — US disclosed
US-10370343-B2 [6,6] Fused bicyclic HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-08-06 — — US disclosed
US-10370343-B2 [6,6] Fused bicyclic HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-08-06 — — US disclosed
US-5200407-A Antisecretory agents MEIJI SEIKA KABURHIKI KAISHA (JP) 1993-04-06 — — US disclosed
US-5141946-A Antisecretory agents; acid resistance MEIJI SEIKA KABUSHIKI KAISHA (JP) 1992-08-25 — — US disclosed
EP-0222576-B1 HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS PFIZER INC. (US) 1992-03-18 — — EP disclosed
US-5079255-A Nontoxic, acid stability MEIJI SEIKA KABUSHIKI KAISHA (JP) 1992-01-07 — — US disclosed
EP-0405976-A1 Azole derivatives and antiulcerative composition containing same MEIJI SEIKA KABUSHIKI KAISHA (JP) 1991-01-02 — — EP disclosed
US-4939140-A ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1990-07-03 — — US disclosed
EP-0313202-A2 Process for preparing halomethyl thiazoles PFIZER INC. (US) 1989-04-26 — — EP disclosed
US-4748280-A Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6) PFIZER INC. (US) 1988-05-31 — — US disclosed
US-4723010-A Process for preparing chloromethyl thiazoles or oxazoles, and intermediates for use therein PFIZER INC. (US) 1988-02-02 — — US disclosed
EP-0222576-A2 Heterocyclic oxophthalazinyl acetic acids PFIZER INC. (US) 1987-05-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406830-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS HDAC8, HDAC3, HDAC2 PDK1 552/4885POLB 2819/4885NPC1 2435/4885
US-20210139439-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS HDAC8, HDAC3, HDAC2 PDK1 552/4885POLB 2819/4885NPC1 2435/4885
US-10370343-B2 [6,6] Fused bicyclic HDAC8 inhibitors HDAC8, HDAC3, HDAC2 PDK1 552/4885POLB 2819/4885NPC1 2435/4885
US-11414392-B2 [6,6] fused bicyclic HDAC8 inhibitors HDAC8, HDAC3, HDAC2 PDK1 552/4885POLB 2819/4885NPC1 2435/4885
US-20190308946-A1 [6,6] FUSED BICYCLIC HDAC8 INHIBITORS HDAC8, HDAC3, HDAC2 PDK1 552/4885POLB 2819/4885NPC1 2435/4885
US-10829460-B2 [6,6] fused bicyclic HDAC8 inhibitors HDAC8, HDAC1, HDAC2 PDK1 613/4885POLB 2117/4885NPC1 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.